K. Adams

发表

Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study

M. Exline, Akram Khan, W. Self, 2022, BMJ.

Protection of mRNA vaccines against hospitalized COVID-19 in adults over the first year following authorization in the United States

M. Exline, Akram Khan, W. Self, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study

M. Exline, Akram Khan, W. Self, 2022, BMJ.

Vaccine Effectiveness of Primary Series and Booster Doses against Omicron Variant COVID-19-Associated Hospitalization in the United States

A. Monto, D. Hager, N. Shapiro, 2022, medRxiv.

Effectiveness of mRNA Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death — United States, March 2021–January 2022

M. Exline, Akram Khan, W. Self, 2022, MMWR. Morbidity and mortality weekly report.

Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults — United States, August–December 2021

Manish M Patel, M. Exline, Akram Khan, 2022, MMWR. Morbidity and mortality weekly report.

Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity.

M. Exline, Akram Khan, W. Self, 2021, JAMA.

Immunogenicity of Pfizer-BioNTech COVID-19 mRNA Primary Vaccination Series in Recovered Individuals Depends on Symptoms at Initial Infection.

J. Corbeil, G. Boivin, J. Carbonneau, 2022, medRxiv.

A literature review of severity scores for adults with influenza or community-acquired pneumonia – implications for influenza vaccines and therapeutics

Manish M Patel, W. Self, E. Chow, 2021, Human vaccines & immunotherapeutics.

Prevalence of SARS-CoV-2 and Influenza Coinfection and Clinical Characteristics Among Children and Adolescents Aged <18 Years Who Were Hospitalized or Died with Influenza — United States, 2021–22 Influenza Season

L. Brammer, W. Schaffner, C. Reed, 2022, MMWR. Morbidity and mortality weekly report.

Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022.

M. Exline, Akram Khan, W. Self, 2022, MMWR. Morbidity and mortality weekly report.

Absolute and Relative Vaccine Effectiveness of Primary and Booster Series of COVID-19 Vaccines (mRNA and Adenovirus Vector) Against COVID-19 Hospitalizations in the United States, December 2021–April 2022

M. Exline, Akram Khan, W. Self, 2022, Open forum infectious diseases.

Comparison of test-negative and syndrome-negative controls in SARS-CoV-2 vaccine effectiveness evaluations for preventing COVID-19 hospitalizations in the United States

M. Exline, Akram Khan, W. Self, 2022, Vaccine.

Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021–February 2022, VISION Network: a retrospective cohort study

R. Link-Gelles, P. Embí, K. Natarajan, 2023, Lancet regional health. Americas.

Comparison of mRNA vaccine effectiveness against COVID-19-associated hospitalization by vaccination source: Immunization information systems, electronic medical records, and self-report—IVY Network, February 1–August 31, 2022

Akram Khan, W. Self, A. Ginde, 2023, Vaccine.

Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023.

S. E. Reese, C. Mcevoy, R. Link-Gelles, 2023, American Journal of Transplantation.

Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19–Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions — VISION Network, September 2022–April 2023

William F. Fadel, S. E. Reese, C. Mcevoy, 2023, MMWR. Morbidity and mortality weekly report.

Effectiveness of the Ad26.COV2.S (Johnson & Johnson) COVID-19 Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States

M. Exline, Akram Khan, W. Self, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.